300 North Capital’s Ionis Pharmaceuticals IONS Stock Holding History

300 North Capital’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-26,024	Closed	-$1.66M	–	61
2015 Q1	$1.66M	Sell	26,024 -584	-2%	-$39.6K	0.36%	90
2014 Q4	$1.64M	Buy	26,608 +44	+0.2%	+$2.17K	0.38%	83
2014 Q3	$1.03M	Buy	26,564 +700	+3%	+$24.8K	0.27%	92
2014 Q2	$892K	Hold	25,864	–	–	0.22%	84
2014 Q1	$1.12M	Buy	+25,864	New	+$1.25M	0.29%	80

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

300 North Capital's IONS Position: Q2 2015 in Review

300 North Capital sold out of Ionis Pharmaceuticals (IONS) in Q2 2015, closing a stake of 26,024 shares — an estimated $1.66M sold.

300 North Capital first reported a position in IONS in Q1 2014 and held it in 5 quarters. The position peaked at $1.66M in Q1 2015. 353 funds tracked by Wall St. Rank hold IONS as of Q2 2015.

300 North Capital reported no remaining Ionis Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
300 North Capital sold 26,024 Ionis Pharmaceuticals shares in Q2 2015, an estimated $1.66M.
300 North Capital first reported a position in Ionis Pharmaceuticals in Q1 2014 and held it in 5 quarters.
300 North Capital's Ionis Pharmaceuticals position peaked at $1.66M in Q1 2015.
353 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2015.

Based on 300 North Capital's 13F filing for Q2 2015, filed 30 Jul 2015.